Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further deve ...

Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial • 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibr ...